Lilopristone
 | |
| Clinical data | |
|---|---|
| Other names | ZK-98734; ZK-734; 11β-(4-(Dimethylamino)phenyl)-17β-hydroxy-17α-((Z)-3-hydroxypropenyl)estra-4,9-dien-3-one |
| Identifiers | |
| |
JSmol) | |
| |
| |
Lilopristone (
synthetic, steroidal antiprogestogen with additional antiglucocorticoid activity which was developed by Schering and was patented in 1985.[1][2][3][4] It is described as an abortifacient and endometrial contraceptive.[1][4][5] The drug differs from mifepristone only in the structure of its C17α side chain, and is said to have much reduced antiglucocorticoid activity in comparison.[6]
See also
References
- ^ ISBN 978-1-4757-2085-3.
- ISBN 978-81-312-1526-5.
- ISBN 978-3-662-09153-1.
- ^ ISBN 978-1-351-78989-9.
- ISBN 978-93-5250-028-4.
- ISBN 978-0-19-563630-7.
[...] lilopristone, which differs from mifepristone only in the structure of the 17a side chain, is said to have a much reduced antiglucocorticoid activity (Neef et al., 1984).
Further reading
- Puri CP, Katkam RR, D'Souza A, Elger WA, Patil RK (September 1990). "Effects of progesterone antagonist, lilopristone (ZK 98.734), on induction of menstruation, inhibition of nidation, and termination of pregnancy in bonnet monkeys". Biology of Reproduction. 43 (3): 437–43. PMID 2271724.
- Puri CP, Patil RK, Kholkute SD, Elger WA, Swamy XR (July 1989). "Progesterone antagonist lilopristone: a potent abortifacient in the common marmoset". American Journal of Obstetrics and Gynecology. 161 (1): 248–53. PMID 2502015.